A Randomized Phase II Trial of Concurrent Chemoradiation With Cetuximab (ERBITUX®), 5 Fluorouracil, Hydroxyurea, and Twice-daily Radiation (CetuxFHX) Versus Cetuximab (ERBITUX®), Cisplatin, and Accelerated Radiation With Concomitant Boost (CetuxPX) After Induction Chemotherapy in Patients With Locally Advanced Head and Neck Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
progression free survival (PFS) and overall survival (OS)
1-year and 2-year progression free survival as well as overall survival
No
Everett E Vokes, MD
Principal Investigator
University of Chicago
United States: Institutional Review Board
14401A
NCT00468169
July 2006
November 2012
Name | Location |
---|---|
University of Chicago | Chicago, Illinois 60637 |